Alkem Launches Neuceno for Epilepsy Treatment

has launched Neuceno (cenobamate) in India for the treatment of partial-onset seizures in adult patients, marking the first launch of cenobamate in the Indian market, according to the company announcement. The product expands Alkem’s presence in the neurology/CNS segment, where the company already offers a broad portfolio of therapies. Neuceno is an oral, once-daily anti-seizure therapy available in multiple dosage strengths, providing flexibility for physicians to individualize treatment. Cenobamate is an established treatment for partial-onset seizures in adults; U.S. prescribing information describes once-daily dosing with gradual titration and maintenance dosing based on clinical response and tolerability. The launch is relevant because epilepsy management often requires long-term therapy and appropriate dose optimization. The availability of a new molecule in India could broaden treatment options for adult patients whose seizures require additional or alternative therapeutic approaches. Alkem has an established presence in CNS and neurology and operates a large India-focused commercial network, which can support the product’s reach among healthcare professionals. From a business perspective, the launch strengthens Alkem’s specialty and chronic-care portfolio and provides an opportunity to participate in the domestic market for newer anti-seizure therapies. However, the eventual commercial contribution will depend on physician adoption, pricing, reimbursement/accessibility, competition from existing anti-epileptic medicines and the pace of patient uptake. Cenobamate also carries important prescribing considerations, including gradual titration and safety warnings, meaning treatment should be initiated and adjusted under appropriate medical supervision.